SOURCE: Trimedyne, Inc.

June 13, 2007 09:30 ET

MN1.com to Interview Trimedyne's Chairman Live on June 14

LAKE FOREST, CA--(Marketwire - June 13, 2007) - TRIMEDYNE, INC. (OTCBB: TMED) today announced its chairman, Dr. Marvin P. Loeb, will be interviewed live on Market News First (MN1.com) at 3:30 p.m. Eastern Time on Thursday, June 14, 2007. The interview can be heard by going to www.MN1.com.

Dr. Loeb will discuss the Company's worldwide marketing alliance with Boston Scientific and Lumenis, Ltd., who will distribute Trimedyne's new Side Firing Laser Fiber as an accessory to Lumenis' Holmium Lasers for the treatment of enlarged prostates in men. About 50% of men over age 55 suffer from an enlarged prostate, an estimated $700 million annual market. Dr. Loeb will also describe the $600 million potential market for the Company's outpatient laser procedures to treat herniated or ruptured discs in the spine, its four consecutive years of profitability and its current financial condition.

Commenting on the upcoming interview, Dr. Loeb said, "We are pleased that Market News First has chosen to interview us, and we are gratified by the attention being paid to Trimedyne's four years of profitability and the potential for growth due to Trimedyne's worldwide marketing alliance with Boston Scientific and Lumenis and Trimedyne's outpatient spinal disc procedures."

About MN1.com

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live interview web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily interviews, MN1 alerts investors on promising companies and the newest opportunities in the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies and provides insight into the companies' present condition and future plans.

About Trimedyne, Inc.

Trimedyne is a leading manufacturer of proprietary medical lasers and patented fiber optic devices for performing a variety of minimally invasive procedures as less traumatic, lower cost alternatives to traditional surgery. For additional information, visit Trimedyne's website at http://www.trimedyne.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release and the above mentioned interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

Contact Information